In short
Gepotidacin is an investigational antibiotic being studied for urinary tract infections. It is currently in clinical trials, including a Phase 1 study in children aged 2 to under 12 years with suspected or confirmed bacterial infections. The trial involves 20 participants and measures how the body processes a single oral dose of the medicine. Gepotidacin is also being compared with nitrofurantoin, a commonly used antibiotic, for treating uncomplicated urinary tract infections in adults.
Key points
- Gepotidacin is an investigational antibiotic that blocks bacterial DNA replication.
- It is being studied in a Phase 1 trial in children aged 2 to under 12 years.
- The trial includes 20 participants and uses a single oral dose.
- The medicine is given as a powder for oral suspension.
- Gepotidacin has been compared with nitrofurantoin for uncomplicated urinary tract infections in adults.
- The trial is currently authorised but not yet recruiting.
What is gepotidacin?
Gepotidacin is a chemically synthesised antibiotic that belongs to the class of antibacterials known as triazaacenaphthylene compounds. It is an investigational substance, which means it has not yet received marketing authorisation in the product records reviewed here. The medicine is also known by its development code GSK2140944 and the trade name Blujepa. Gepotidacin is classified under the Anatomical Therapeutic Chemical (ATC) code J01XX13, which places it among other antibacterials for systemic use. The company developing gepotidacin is GlaxoSmithKline Research & Development Limited. A paediatric formulation of gepotidacin exists, prepared as a powder for oral suspension.
How does gepotidacin work?
Gepotidacin works by inhibiting two bacterial enzymes that are essential for copying bacterial DNA: DNA gyrase and topoisomerase IV. These enzymes help bacteria unwind and separate their DNA so they can divide and multiply. By blocking them, gepotidacin prevents bacteria from replicating, which stops the infection from spreading. This mechanism is different from many other antibiotics, which target the bacterial cell wall or protein production. Because gepotidacin acts on a different target, it may be active against bacteria that have become resistant to other antibiotics.
Which conditions is gepotidacin studied for?
- Uncomplicated urinary tract infection: Gepotidacin has been compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infections in adults.
- Urinary tract infections in children: A Phase 1 trial is studying a single oral dose of gepotidacin in children aged 2 to under 12 years with suspected or confirmed bacterial infections.
How is gepotidacin given?
Gepotidacin is given by mouth. In the product records reviewed, it is prepared as a powder for oral suspension, which means the powder is mixed with liquid before swallowing. The Phase 1 trial in children uses a single oral dose. In studies in adults with uncomplicated urinary tract infection, gepotidacin was given as an oral antibiotic.
What do the clinical trials show?
One clinical trial of gepotidacin is described in the registry data. It is a Phase 1, open-label, single-arm study in 20 paediatric participants aged 2 to under 12 years with a suspected or confirmed bacterial infection or receiving antibiotic prophylaxis. The trial is authorised but not yet recruiting. Its main purpose is to measure how the body absorbs, distributes and eliminates a single oral dose of gepotidacin. The primary outcomes include the maximum observed plasma concentration (Cmax), the area under the concentration-time curve (AUC), which reflects total drug exposure over time, and the terminal phase half-life (t1/2), which shows how long the medicine stays in the body. These measures help researchers understand the right dose for children. The trial does not compare gepotidacin with another medicine, and it is not designed to show whether the drug cures infections in children.
What side effects are known?
In a plain language summary of a study comparing gepotidacin with nitrofurantoin in adults with uncomplicated urinary tract infection, the authors describe the efficacy and safety of gepotidacin. The summary does not provide a detailed list of side effects, but it discusses the safety profile of the new oral antibiotic compared with a commonly used antibiotic. The registry record for the paediatric trial does not report side effects, as it is an early-phase pharmacokinetic study.